China Business Network reported on August 27 that on August 25, the adsorbed tetanus vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Beijing Kexing Holdings (Group) Co., Ltd., obtained the "Drug Registration Certificate" issued by the National Medical Products Administration (Approval Number: National Medicine Standard S20250048), which will provide more options for tetanus prevention.
Sinovac's adsorbed tetanus vaccine uses an aluminum hydroxide adjuvant with a particle size of only 300 nanometers (compared to traditional adjuvants of 1-10 microns), which improves antigen adsorption efficiency and significantly enhances formulation stability. By upgrading the purification process, the tetanus vaccine concentrate has better immunogenicity.
According to the "Guidelines for the Diagnosis and Treatment of Non-Neonatal Tetanus (2024 Edition)", tetanus remains a serious public health problem in countries and regions where immunization programs are not fully implemented. It is estimated that there are approximately 1 million cases of tetanus and 300,000 to 500,000 deaths worldwide each year. Tetanus vaccine can be used to prevent tetanus after trauma and for pre-exposure prophylaxis in individuals at high risk of potential trauma.
Non-neonatal tetanus is an acute, specific, toxic disease characterized by sustained tetanic contractions and paroxysmal spasms of skeletal muscles throughout the body, caused by Clostridium tetani invading the body through breaks in the skin or mucous membranes, where it multiplies and produces exotoxins in an anaerobic environment. Severe cases can cause laryngospasm, asphyxia, lung infection, and organ failure. Without medical intervention, the mortality rate approaches 100%. Even with aggressive comprehensive treatment, the global mortality rate remains between 30% and 50%, making it an extremely serious and potentially fatal disease.
In recent years, Sinovac Biotech has actively developed its presence in the trauma field, with adsorbed tetanus vaccine being a key product in the company's "trauma combination product" strategy. In addition to vaccines, the company is also advancing clinical research on the anti-tetanus toxin monoclonal antibody SNA02-48 injection. Furthermore, the company's investment in Xingmeng Biopharmaceuticals has developed a Class 1 innovative drug.Crebi® was approved for marketing in 2024 for passive immunotherapy of adults exposed to rabies virusSinovac Biotech (Chengdu)The marketing application for the freeze-dried human rabies vaccine (serum-free Vero cells) developed by Co., Ltd. was also accepted in January 2025.

https://finance.eastmoney.com/a/202508273496371042.html